Research Article
Modeling Drug-Carrier Interaction in the Drug Release from Nanocarriers
Table 3
Parameter estimates for simulations in Figure
5.
| Drug/Carriera | Mechanisms | Variables | Model parametersb | | | (10−21 J) |
|
DoxorubicinPLLA fibers [14] | Hydrophobicity | dox hydrochloride | 0.027a | 0.001a | 7.4 | dox base | 0.041a | 0.0004a | −6.65 | | | 100 : 0 AG/HP | 11.1c | 0.095c | 1.03 |
Avidin CS-AG fibers [7] | | 80 : 20 AG/HP | 11.2c | 0.064c | −2.37 | Heparin addition | 90 : 10 AG/HP | 5.12c | 0.053c | −2.09 | | 50 : 50 AG/HP | 9.89c | 0.045c | −2.64 |
PDGF CS-AG fibers [7] | | 100 : 0 AG/HP | 0.677c | 0.027c | −4.14 | | 90 : 10 AG/HP | 0.486c | 0.001c | −13.5 |
VEGFPEtU-PDMS/fibrin fibers [15] | | 10 mg/mL fibrin | 0.435c | 0.009c | 0.187 | Fibrin concentration | 20 mg/mL fibrin | 0.434c | 0.017c | −1.27 |
bFGFPEtU-PDMS/fibrin fibers [15] | 10 mg/mL fibrin | 0.289c | 0.001c | 0.65 | | 20 mg/mL fibrin | 0.242c | 0.017c | −1.94 |
GSMBGHFs [16] | Fiber length | 2–2.5 mm | 0.444b | 0.005b | 7.24 | 5–10 mm | 0.136b | 0.012b | 5.13 | BSAhydrogel nanofibers | | 37°C | 4.81c | 0.027c | −4.9 | Temperature | 25°C | 1.585c | 0.017c | −5.47 |
BSAPCL fibers [31] | 37°C | 1.114c | 0.011c | −4.72 | | 25°C | 1.521c | 0.011c | −6.33 |
|
|
aPLLA: poly(L-lactide), Dox: doxorubicin, CS: chitosan, AG: alginate, HP: heparin, PDGF: recombinant human platelet derived growth factor, VEGF: vascular endothelial growth factors, bFGF: basic fibroblast growth factors, PEtU-PDMS: poly(ether)urethane-polydimethylsiloxane, GS: gentamicin sulfate, MBGHFs: mesoporous bioactive glass hollow fibers, BSA: bovine serum albumin, hydrogel fibers: poly(PEG/PPG/PCL urethane) hydrogel fibers, PEG: poly(ethylene glycol), PPG: poly(propylene glycol), and PCL: poly(ε-caprolactone). and have different units in different cases: M: minute−1, H: hour−1, and D: day−1.
|